Investor Centre

Our broad clinical and preclinical pipeline in oncology and behavioural brain disorders focuses on indications including glioblastoma, neurodevelopmental disorders, addiction, anxiety, fatigue and narcolepsy.
Stat background
0.53 GBX Volume: 10,497 Market Capitalisation (m) £2.26

TheraCryf plc Full Year Results

Results_Cover_May24
29 - May - 2024
Current corporate presentation

Voting on AGM Resolutions

18 - July - 2024
Results of voting on resolutions following TheraCryf's AGM held on Thursday 18th July 2024.

TheraCryf plc - half-year results

28 - November - 2024
CEO Huw Jones and CFO Toni Haenninen present TheraCryf's half-year results

Major Shareholder

Current ShareholderNumber of sharesPercentage holding
J. R. Kight34,600,000 8.10%
First Equity Limited31,200,0007.30%
Rathbones Investment Management Ltd25,789,2466.03%
Octopus Investments21,875,0005.12%
Vulpes Investment Management Pte Ltd20,554,1914.81%
Seneca Partners Limited16,301,4563.81%
The number of ordinary shares in issue is 429,622,422 all of which are in public hands. The Company does not hold any shares in Treasury.
Last updated 21 November 2024